Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease

Vergaro, Giuseppe; Aimo, Alberto; Januzzi, James L.; Richards, A. Mark; Lam, Carolyn S.P.; Latini, Roberto; Staszewsky, Lidia; Anand, Inder S.; Ueland, Thor; Rocca, Hans Peter Brunner La

Published in:
Journal of cardiovascular medicine (Hagerstown, Md.)

DOI:
10.2459/JCM.0000000000001281

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease

Giuseppe Vergaro\textsuperscript{a,b}, Alberto Aimo\textsuperscript{a*}, James L. Januzzi Jr.\textsuperscript{c}, A. Mark Richards\textsuperscript{d}, Carolyn S.P. Lam\textsuperscript{e}, Roberto Latini\textsuperscript{i}, Lidia Staszewsky\textsuperscript{f}, Inder S. Anand\textsuperscript{g,h}, Thor Ueland\textsuperscript{i,j,k}, Hans-Peter Brunner-La Rocca\textsuperscript{l}, Antoni Bayes-Genis\textsuperscript{m}, Josep Lupón\textsuperscript{m}, Rudolf A. de Boer\textsuperscript{n}, Akiomi Yoshihisa\textsuperscript{o}, Yasuchika Takeishi\textsuperscript{o}, Ida Gustafsson\textsuperscript{p}, Kai M. Eggers\textsuperscript{q}, Kurt Huber\textsuperscript{r}, Greg D. Gamble\textsuperscript{s}, Kui Toh Gerard Leong\textsuperscript{t}, Poh Shuan Daniel Yeo\textsuperscript{u}, Hean Yee Ong\textsuperscript{v}, Fazlur Jafeera\textsuperscript{w}, Tze P. Ng\textsuperscript{t}, Richard Troughton\textsuperscript{d}, Robert N. Doughty\textsuperscript{s}, Michele Emdin\textsuperscript{a,b} and Claudio Passino\textsuperscript{a,b}

\textbf{Aims} Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity in patients with heart failure (HF). We assessed the influence of COPD on circulating levels and prognostic value of three HF biomarkers: N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), and soluble suppression of tumorigenesis-2 (sST2).

\textbf{Methods} Individual data from patients with chronic HF, known COPD status, NT-proBNP and hs-TnT values (\(n = 8088\)) were analysed. A subgroup (\(n = 3414\)) had also sST2 values.

\textbf{Results} Patients had a median age of 66 years (interquartile interval 57–74), 77% were men and 82% had HF with reduced ejection fraction. NT-proBNP, hs-TnT and sST2 were 1207 ng/l (487–2725), 17 ng/l (9–31) and 30 ng/ml (22–44), respectively. Patients with COPD (\(n = 1249, 15\%\)) had higher NT-proBNP (\(P = 0.042\)) and hs-TnT (\(P < 0.001\)), but not sST2 (\(P = 0.165\)). Over a median 2.0-year follow-up (1.5–2.5), 1717 patients (21\%) died, and 1298 (16\%) died from cardiovascular causes; 2255 patients (28\%) were hospitalized for HF over 1.8 years (0.9–2.1). NT-proBNP, hs-TnT and sST2 predicted the three end points regardless of COPD status. The best cut-offs from receiver-operating characteristics analysis were higher in patients with COPD than in those without. Patients with all three biomarkers higher than or equal to end-point- and COPD-status-specific cut-offs were also those with the worst prognosis.

\textbf{Conclusions} Among patients with HF, those with COPD have higher NT-proBNP and hs-TnT, but not sST2. All these biomarkers yield prognostic significance regardless of the COPD status.

\textbf{Keywords:} biomarkers, chronic obstructive pulmonary disease, heart failure, prognosis

\textsuperscript{a}Scuola Superiore Sant’Anna, \textsuperscript{b}Fondazione Toscana G. Monasterio, Pisa, Italy, \textsuperscript{c}Massachusetts General Hospital and Baim Institute for Clinical Research, Boston, Massachusetts, USA, \textsuperscript{d}University of Otago, New Zealand, \textsuperscript{e}National Heart Centre Singapore and Duke-National University of Singapore, Singapore, \textsuperscript{f}IRCCS – Istituto di Ricerche Farmacologiche ‘Mario Negri’, IRCCS Milano, Italy, \textsuperscript{g}University of Minnesota, \textsuperscript{h}VA Medical Centre, Minneapolis, Minnesota, USA, \textsuperscript{i}Oslo University Hospital, Ullern, \textsuperscript{j}Oslo University Hospital, Rikshospitalet, Oslo, \textsuperscript{k}University of Tromsø, Tromsø, Norway, \textsuperscript{l}Maastricht University Medical Centre, Maastricht, The Netherlands, \textsuperscript{m}Hospital Universitari Germans Trias i Pujol, Badalona (Barcelona) and CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain, \textsuperscript{n}University Medical Centre Groningen, Groningen, The Netherlands, \textsuperscript{o}Fukushima Medical University, Fukushima, Japan, \textsuperscript{p}Copenhagen University Hospital Rigshospitalet, Denmark, \textsuperscript{q}Uppsala University, Uppsala, Sweden, \textsuperscript{r}Wilhelminenspital and Sigmund Freud University Medical School, Vienna, Austria, \textsuperscript{s}University of Auckland, New Zealand, \textsuperscript{t}Tan Tock Seng Hospital, Khoo Teck Puat Hospital and \textsuperscript{u}Singapore General Hospital, Singapore

Correspondence to Alberto Aimo, MD, Institute of Life Sciences, Scuola Superiore Sant’Anna; Cardiology Division, Fondazione Toscana Gabriele Monasterio, Pisa, Italy, Piazza Martini della Libertà 33, 56124 Pisa, Italy Tel: +39 3477084391; e-mail: a.aimo@santannapisa.it, aimoalb@ftgm.it

Received 14 July 2021 Revised 1 November 2021 Accepted 6 November 2021

\textbf{doi:} 10.2459/JCM.0000000000001281

\textbf{© 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.}
with worse outcome in patients with HF, both in study registries such as the HF Long-Term Registry of the European Society of Cardiology and in post-hoc analyses of clinical trials such as the SHIFT (Systolic Heart failure treatment with the IF inhibitor ivabradine Trial) trial. The interplay between COPD diagnosis, HF biomarkers and outcome has been less extensively explored.

B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) do not display a prominent increase in patients with stable COPD but no HF, but can be elevated and hold prognostic value in patients with COPD exacerbations. Conversely, patients with stable chronic HF and also COPD have higher NPs than those with HF but no COPD. In patients hospitalized for acute HF and evaluated after haemodynamic stabilization, COPD severity, measured as the forced expiratory volume in the first second or alveolar volume, was correlated with NT-proBNP.

Troponin T (TnT) and soluble suppression of tumorigenesis-2 (sST2) are other HF biomarkers with an established prognostic value. Circulating TnT is higher in patients with HF and COPD than in those without COPD. In a small study, the median sST2 concentration was 2.5-fold higher in patients with HF, and 5-fold higher in patients with COPD than controls ( n = 15 in all groups). In a larger cohort, Martinez-Rumayor et al. reported that higher sST2 yielded prognostic significance among patients with primary pulmonary disorders, including COPD, although sST2 was measured through an early generation, lower-precision assay.

In the present study, we focused on the relationship between COPD status, circulating levels and prognostic value of NT-proBNP, hs-TnT and sST2 in a large international cohort of patients with chronic HF.

**Methods**

**Patient population**

The BIomarkers Of heart failure Study (BIOS) consortium includes 14 cohorts of patients with stable chronic HF. This consortium was created by merging the dataset created for a previous individual patient data meta-analysis on hs-TnT and outcome ( n = 9289) with other cohorts of patients with stable HF, namely the Prospective Evaluation of Outcome in Patients with heart failure with preserved Left ventricular Ejection fraction (PEOPLE), the Singapore Heart failure Outcomes and Phenotypes (SHOP) cohorts ( n = 941 and 1099, respectively), an additional cohort of HF outpatients from the Hospital Universitari Germans Trias i Pujol, Barcelona, Spain ( n = 1589) and an Institutional dataset of the Fondazione Toscana Gabriele Monasterio, Pisa, Italy ( n = 2763). The total patient number was 15 681. For the present study, we considered only the patients ( n = 8088) with available NT-proBNP and hs-TnT and COPD status (present or absent) adjudicated based on the clinical judgment of the investigators of the original cohorts, taking into account the patient’s medical history, treatment and/or spirometry data.

**Laboratory evaluation**

In all studies, NT-proBNP was measured through the monoclonal electrochemiluminescence immunoassay method [Roche Diagnostics; coefficient of variation (CV) <3% at cut-off value (150 ng/l)], and TnT through the Roche Diagnostics assay [Basel, Switzerland; limit of blank 3 ng/l, limit of detection (LOD) 5 ng/l, 99th percentile value in apparently healthy individuals of 14 ng/l]. In a subgroup of patients ( n = 3418, 26%), sST2 was measured through the Presage assay (LOD 1.3 ng/ml, measurement range up to 200 ng/ml, intra-assay CV <7%, inter-assay CV <9%). These biomarkers were assayed in a core laboratory for each study. Samples were collected during an outpatient visit; patients had been clinically stable, with no need for changes in therapy for at least 1 month. The estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology collaboration equation; patients on dialysis were excluded.

**Statistical analysis**

IBM SPSS Statistics (version 22, 2013) and R statistical software (http://www.r-project.org/, version 3.4.4) were used. Normal distribution was assessed by plotting a histogram and running the Kolmogorov–Smirnov test; variables with normal distribution were presented as mean ± standard deviation, while those with nonnormal distribution were presented as medians and interquartile intervals. Missing data were discarded and not imputed. Mean differences among groups were evaluated through the unpaired Student’s t-test or the Mann–Whitney U test, as appropriate. Categorical variables were compared by the chi-square test with Yates correction. The β coefficients were computed at multivariate linear regression analysis. Multicollinearity was searched by calculating the Variance Inflation Factor, with a threshold of 5. Schoenfeld residuals were evaluated to check the proportional hazards assumption. Uni- and multivariate Cox regression analysis was performed to search for predictors of three end points: all-cause death, cardiovascular death and HF hospitalization. The Fine-Gray model was used to account for mutually exclusive end points; non-cardiovascular death was considered as a competing risk for cardiovascular death, and all-cause death for HF hospitalization. The multivariate models for the three end points included all univariate predictors with P < 0.050, excluding colinear variables. Separate models were created for patients with NT-proBNP and hs-TnT values or those with also sST2 values: all-cause death, NT-proBNP and hs-TnT; age, sex, New York Heart Association (NYHA) class III–IV, eGFR, left ventricular ejection fraction (LVEF), therapy with beta blockers, COPD, NT-proBNP and hs-TnT; all-cause death, NT-proBNP, ...
hs-TnT and sST2: age, sex, NYHA III–IV, LVEF, beta blockers, NT-proBNP, hs-TnT, sST2; cardiovascular death, NT-proBNP and hs-TnT: age, sex, NYHA III–IV, eGFR, LVEF, beta blockers, NT-proBNP, hs-TnT; cardiovascular death, NT-proBNP, hs-TnT and sST2: age, sex, NYHA III–IV, eGFR, LVEF, beta blockers, NT-proBNP, hs-TnT; sST2; HF hospitalization, NT-proBNP and hs-TnT: diabetes, NYHA III–IV, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB), mineralocorticoid receptor antagonists (MRA), COPD, NT-proBNP, hs-TnT; HF hospitalization, NT-proBNP, hs-TnT and sST2: body mass index, diabetes, NYHA III–IV, eGFR, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB), MRA, COPD, NT-proBNP, hs-TnT, sST2 (Table 3). Cubic spline interpolation was carried out to represent the changes in risk according to biomarker values; five knots were considered. Area under the curve (AUC) values were compared through the DeLong’s test, and the best cut-offs were searched through the Youden method. Two-tailed P-values of <0.05 were deemed significant.

Results

Patient population

Patients (n = 8088) had a median age of 66 years (inter-quartile interval 57–74), 77% were men, and 82%, 6%, 8% had HF with reduced, mid-range, or preserved ejection fraction (HFrEF/HFmrEF/HFpEF), respectively (the remaining patients had missing LVEF data). Patients with COPD (n = 1249, 15%) were older [age 70 years (62–77) vs. 65 (56–73); P < 0.001] and more often men (80% vs. 77%; P = 0.019), had more severe dyspnoea (46% in NYHA class III–IV vs. 33%; P < 0.001), and were less often on beta blockers (46% vs. 59%, P < 0.001; Table 1). COPD independently predicted hs-TnT, while it was just a univariate predictor of NT-proBNP, and did not predict sST2 even at univariate analysis (Table 2). Similar results emerged from an analysis restricted to patients with HFrEF (Table 1, Supplemental Digital Content, http://links.lww.com/JCM/A433).

Chronic obstructive pulmonary disease and biomarkers

In the whole cohort, NT-proBNP and hs-TnT were 1207 ng/L (487–2725) and 17 ng/L (9–31), respectively. In the subgroup with sST2 values available (n = 3414), sST2 was 30 ng/ml (22–44). Patients with COPD had higher NT-proBNP (P = 0.042) and hs-TnT (P < 0.001). sST2 did not differ significantly between patients with COPD (n = 491, 14%) vs. those without (P = 0.165; Table 1).

Predictors of NT-proBNP, hs-TnT and (in the subgroup with available values) sST2 were searched among population characteristics from Table 1. COPD independently predicted hs-TnT, while it was just a univariate predictor of NT-proBNP, and did not predict sST2 even at univariate analysis (Table 2). Similar results emerged from an analysis restricted to patients with HFrEF (Table 1, Supplemental Digital Content, http://links.lww.com/JCM/A433).

Chronic obstructive pulmonary disease, biomarkers and outcome

Over a median 2.0-year follow-up (1.5–2.5), 1717 patients (21%) died and 1298 (16%) died from cardiovascular causes. Furthermore, 2255 patients (28%) were hospitalized for HF over 1.8 years (0.9–2.1). For each one of the three end points, we searched the univariate predictors among baseline characteristics, and we included them in multivariate models. COPD predicted all-cause death and HF hospitalization independently from NT-proBNP and hs-TnT, but lost its independent prognostic value when sST2 was included in the model (decreasing the number of patients available for analysis). Conversely, NT-proBNP, hs-TnT and sST2 predicted the three end points regardless of COPD status (Table 3). In patients with HFrEF, COPD status did not independently

Table 1  Patient characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Missing values, n (%)</th>
<th>Whole population n = 8088</th>
<th>Yes (n = 1249, 15%)</th>
<th>No (n = 6839, 85%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>0 (0)</td>
<td>66 (57–74)</td>
<td>70 (62–77)</td>
<td>65 (56–73)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>0 (0)</td>
<td>6249 (77)</td>
<td>997 (80)</td>
<td>5252 (77)</td>
<td>0.19</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>210 (3)</td>
<td>26 (24–30)</td>
<td>27 (24–31)</td>
<td>26 (24–30)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>6 (0)</td>
<td>4300 (53)</td>
<td>734 (59)</td>
<td>3566 (52)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AF, n (%)</td>
<td>2 (0)</td>
<td>2574 (32)</td>
<td>409 (33)</td>
<td>2165 (32)</td>
<td>0.451</td>
</tr>
<tr>
<td>NYHA II–IV, n (%)</td>
<td>188 (2)</td>
<td>2854 (35)</td>
<td>568 (46)</td>
<td>2285 (33)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>eGFR (ml/min/1.73 m²)</td>
<td>52 (1)</td>
<td>58 (46–70)</td>
<td>58 (44–79)</td>
<td>58 (46–70)</td>
<td>0.012</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>267 (3)</td>
<td>30 (23–36)</td>
<td>30 (24–38)</td>
<td>29 (23–36)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>NT-proBNP (ng/ml)</td>
<td>267 (3)</td>
<td>6631, 517, 673 (82, 8, 8)</td>
<td>941, 110, 137 (75, 9, 11)</td>
<td>5690, 407, 536 (83, 8, 8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Beta blockers, n (%)</td>
<td>1 (0)</td>
<td>4635 (57)</td>
<td>570 (46)</td>
<td>4065 (59)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MRA, n (%)</td>
<td>6 (0)</td>
<td>7010 (87)</td>
<td>1074 (86)</td>
<td>5936 (87)</td>
<td>0.442</td>
</tr>
<tr>
<td>NT-proBNP (ng/ml)</td>
<td>8 (0)</td>
<td>1802 (22)</td>
<td>322 (26)</td>
<td>1480 (22)</td>
<td>0.001</td>
</tr>
<tr>
<td>hs-TnT (ng/ml)</td>
<td>0 (0)</td>
<td>1799 (22)</td>
<td>22 (13–38)</td>
<td>17 (9–30)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>sST2 (ng/ml)</td>
<td>4674 (58)</td>
<td>30 (22–44)</td>
<td>31 (23–45)</td>
<td>29 (21–43)</td>
<td>0.165</td>
</tr>
</tbody>
</table>

ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers; AF, atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity troponin T; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonists; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST2, soluble suppression of tumorigenesis-2.
predict all-cause or cardiovascular death, while it predicted HF hospitalization independently of NT-proBNP and hs-TnT, but not sST2 (Table 2, Supplemental Digital Content, http://links.lww.com/JCM/A433).

Influence of chronic obstructive pulmonary disease on the prognostic value of biomarkers

NT-proBNP, hs-TnT and sST2 were all univariate predictors of outcome, and the risk of all-cause death, cardiovascular death and HF hospitalization increased exponentially with rising biomarkers, in both patients with COPD and those without (Fig. 1). In both subgroups, NT-proBNP and hs-TnT displayed similar AUC values and higher than sST2 (Fig. 2 and Table 4, Supplemental Digital Content, http://links.lww.com/JCM/A433). The best cut-offs were always higher in patients with COPD than in those without (Tables 4 and 5, Supplemental Digital Content, http://links.lww.com/JCM/A433). In both subgroups with or without COPD, patients with all three biomarkers higher than or equal to end-point- and COPD-status-specific cut-offs were also those with the worst prognosis (Fig. 3). The best cut-offs in patients with HFrEF were quite close to those calculated in the whole population (Table 6, Supplemental Digital Content, http://links.lww.com/JCM/A433).

Discussion

In a large cohort of patients with chronic HF (n = 8088), patients with COPD (n = 1249, 15%) had higher levels of NT-proBNP and hs-TnT (both P < 0.001), but not sST2 (P = 0.165). NT-proBNP, hs-TnT and sST2 predicted the three end points regardless of COPD status. The best cut-offs from receiver-operating characteristics analysis were higher in patients with COPD than in those without. When stratifying patients based on end-point- and COPD-status-specific cut-offs, the frequency of the end points increased rapidly together with the number of biomarkers ≥ cut-offs.

The comparison between patients with or without COPD confirms the association between this condition and a clinical profile characterized by more advanced age, more severe symptoms and comorbidities. Several factors, such as age,24 lower eGFR values,3 low AF and lower body mass index,42 have been previously associated with higher NT-proBNP; accordingly, circulating NT-proBNP was significantly higher in patients with COPD, but COPD did not display an independent relationship with NT-proBNP. As for hs-TnT, its levels are higher in men and in elderly subjects, leading to the proposal of age-adjusted cut-offs to diagnose myocardial infarction.28 The age-dependent increase in hs-TnT seems partially explained by the concurrent growing burden of comorbidities,29 and reduced renal clearance.30 The relationship between COPD and hs-TnT was even tighter than the one with NT-proBNP or sST2, again possibly because of age, renal dysfunction and comorbidities, but likely also as a result of detrimental effects of chronic inflammation on the myocardium.31 sST2 is classified among inflammatory biomarkers, reflecting the body of evidence indicating a role in inflammatory disorders also beyond the cardiovascular system.32 The lungs are among the main sites of sST2 production, even in patients with HF,33,34 and sST2 may blunt IL-33-mediated inflammation in COPD.15 The finding that sST2 is less affected by the COPD status than NT-proBNP and hs-TnT was therefore unexpected. Nonetheless, a wide distribution of sST2 values with a large overlap between patients with HF and HF plus pneumonia or COPD was previously reported.16,35 One explanation might be that sST2 concentrations are less affected than those of NT-proBNP and hs-TnT by age and renal dysfunction.36,37 We should also remember that sST2 was evaluated in a much smaller number of patients than NT-proBNP and hs-TnT.

© 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
### Table 3: Predictors of outcome

<table>
<thead>
<tr>
<th>Predictor</th>
<th>All-cause death</th>
<th>CV death</th>
<th>HF hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Univariate</td>
<td>Multivariate NT-TnT (n = 7626)</td>
<td>Multivariate NT-TnT-sST2 (n = 3299)</td>
</tr>
<tr>
<td>Age</td>
<td>p &lt; 0.001</td>
<td>p &lt; 0.001</td>
<td>1.01 (1.01–1.02)</td>
</tr>
<tr>
<td>Man</td>
<td>0.003</td>
<td>0.001</td>
<td>1.31 (1.16–1.49)</td>
</tr>
<tr>
<td>BMI</td>
<td>p &lt; 0.001</td>
<td>0.215</td>
<td>–</td>
</tr>
<tr>
<td>Hypertension</td>
<td>p &lt; 0.001</td>
<td>0.318</td>
<td>–</td>
</tr>
<tr>
<td>Diabetes</td>
<td>p &lt; 0.001</td>
<td>0.916</td>
<td>–</td>
</tr>
<tr>
<td>AF</td>
<td>p &lt; 0.001</td>
<td>0.931</td>
<td>–</td>
</tr>
<tr>
<td>NYHA III–IV</td>
<td>p &lt; 0.001</td>
<td>0.004</td>
<td>1.42 (1.28–1.57)</td>
</tr>
<tr>
<td>eGFR</td>
<td>p &lt; 0.001</td>
<td>0.004</td>
<td>0.99 (0.99–0.99)</td>
</tr>
<tr>
<td>LVEF</td>
<td>p &lt; 0.001</td>
<td>0.004</td>
<td>0.99 (0.99–1.00)</td>
</tr>
<tr>
<td>Beta blockers</td>
<td>0.128</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>ACE/ARB</td>
<td>0.032</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MRA</td>
<td>0.040</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>COPD</td>
<td>p &lt; 0.001</td>
<td>0.019</td>
<td>1.16 (1.03–1.31)</td>
</tr>
<tr>
<td>NT-proBNP</td>
<td>p &lt; 0.001</td>
<td>0.002</td>
<td>1.25 (1.20–1.30)</td>
</tr>
<tr>
<td>hs-TnT</td>
<td>p &lt; 0.001</td>
<td>0.001</td>
<td>1.27 (1.21–1.32)</td>
</tr>
<tr>
<td>sST2</td>
<td>p &lt; 0.001</td>
<td>0.001</td>
<td>1.27 (1.16–1.43)</td>
</tr>
</tbody>
</table>

Values of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT) and soluble suppression of tumorigenesis-2 (sST2) were log$_{2}$-transformed. Univariate predictors of the three end points were then included in multivariate models. When both left ventricular ejection fraction (LVEF) and LVEF categories emerged as univariate predictors, the latter was not included in the model. The number of patients available for analysis decreased substantially when including sST2 in the model. AF, atrial fibrillation; BMI, body mass index; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.
All three biomarkers displayed a similar, exponential relationship with all-cause and cardiovascular death and HF hospitalization; hs-TnT and sST2 cut-offs refined risk prediction over the NT-proBNP cut-off alone, confirming the additive prognostic value of hs-TnT and sST2 to NT-proBNP previously reported in the broader population of patients with HF. Therefore, a panel including NT-proBNP, hs-TnT and sST2 assays may help to predict the risk of hard endpoints such as all-cause and cardiovascular mortality, as well as HF hospitalization, but higher cut-offs should be preferably considered in patients with COPD. Whether the more accurate risk stratification derived from our findings can be translated into better patient management ultimately leading to improved patient prognosis remains an open question which should be addressed in dedicated studies.

Limitations

An important study limitation is that the database was created to assess the relationship between circulating biomarkers and outcome, rather than the clinical and prognostic correlates of conditions such as COPD. This comorbidity was recorded in the case report forms according to prespecified criteria for data collection, and it was not possible to ascertain how many patients had undergone pulmonary function testing. Similarly, data on disease severity, smoking habit, or specific therapies were not available. On the other hand, the lack of further details on the COPD diagnosis is a limitation shared with sub-analyses of other registry studies such as the large HF Long-Term Registry. Relevant data such as the size and function of right heart chambers were not collected. Even HF aetiology was not available in most studies, which did not allow us to correlate biomarker levels with specific conditions. Data collection spanned across three decades, from 1997 (when enrolment in the Val-HeFT trial began) to 2020, during a period of great advances in HF treatment. Furthermore, patients with HFmrEF or HFpEF accounted for just 14% of the whole cohort; this does not reflect the real-world HF epidemiology, and does not allow the extension of study conclusions to patients with HFmrEF and HFpEF while increasing population heterogeneity. Additionally, sST2 was measured in 36% of patients, as opposed NT-proBNP and hs-TnT measurement in the whole cohort. Despite extensive adjustment in multivariable models, an effect of residual confounders cannot be excluded. Finally, we did not assess the risk of non-
Biomarkers for outcome prediction: area under the curve (AUC) values. COPD, chronic obstructive pulmonary disease; CV, cardiovascular; HF, heart failure; hs-TnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST2, soluble suppression of tumorigenesis-2. The P-values for the comparisons between AUC values are reported in Table 2, Supplemental Digital Content, http://links.lww.com/JCM/A433.
cardiovascular mortality and hospitalization, although these end points are clinically relevant in patients with COPD and were specifically analysed in the Val-HeFT cohort.

**Conclusion**

Among patients with HF, those with COPD have higher NT-proBNP and hs-TnT, but not sST2. All these biomarkers yield prognostic significance regardless of the COPD status.

**Conflicts of interest**

Disclosures: A.M.R. participates in an advisory board for, and has received in-kind support, research grants and speaker fees from, Roche Diagnostics and in-kind research support from Critical Diagnostics. The UMCG, which employs R.D.B., has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Novo Nordisk and Roche. R.D.B. received speaker fees from Abbott, AstraZeneca, Novartis and Roche. C.S.L. is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic and Vifor Pharma; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Abbott Diagnostics, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Biofourmis, Boehringer Ingelheim, Boston Scientific, Corvia Medical, Cyto-kinetics, Darma Inc., Eko.ai Pte Ltd, JanaCare, Janssen Research & Development LLC, Medtronic, Menarini Group, Merck, MyoKardia, Novartis, Novo Nordisk,

© 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.
et al.

References


